ArticleJournal of cheminformatics2025
E-GuARD: expert-guided augmentation for the robust detection of compounds interfering with biological assays.
Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Relating Model Performance to Embedding Distributions in Molecular Machine Learning.Journal of chemical information and modeling · 2026Article
- From Algorithms to Assets: A Comprehensive Review of AI's Role in Preclinical Drug Discovery and the Hurdles to Clinical Translation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Advanced machine learning for innovative drug discovery.Journal of cheminformatics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Assay interference caused by small organic compounds continues to pose formidable challenges to early drug discovery. Various computational methods have been developed to identify compounds likely to cause assay interference. However, due to the scarcity of data available for model development, the predictive accuracy and applicability of these approaches are limited. In this work, we present E-GuARD, a novel framework seeking to address data scarcity and imbalance by integrating self-distillation, active learning, and expert-guided molecular generation. E-GuARD iteratively enriches the training data with interference-relevant molecules, resulting in quantitative structure-interference relationship (QSIR) models with superior performance. We demonstrate the utility of E-GuARD with the examples of four high-quality data sets on thiol reactivity, redox reactivity, nanoluciferase inhibition, and firefly luciferase inhibition. Our models reached MCC values of up to 0.47 for these data sets, with two-fold or higher improvements in enrichment factors compared to models trained without E-GuARD data augmentation. These results highlight the potential of E-GuARD as a scalable solution to mitigating assay interference in early drug discovery. SCIENTIFIC CONTRIBUTION: We present E-GuARD, an innovative framework that combines iterative self-distillation with guided molecular augmentation to enhance the predictive performance of QSAR models. By allowing models to learn from newly generated, informative compounds through iterations, E-GuARD facilitates the understanding of underrepresented structural patterns and improves performance on unseen data. When applied across different interference mechanisms, E-GuARD consistently outperformed standard approaches. E-GuARD establishes the foundation for further research into dynamic data enrichment and more robust molecular modeling.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.